Want to see HK:1066 full AI Analyst Report?
Top Page
Shandong Weigao Group Medical Polymer Co
(1066)
Select Model
Select Model
Rating:67Neutral
Price Target:
HK$3.50
▲(0.57% Upside)
Action:Reiterated
Date:08/04/26
The score is anchored by stable but weakening financial performance—especially the sharp 2025 revenue drop and margin/ROE erosion—partly offset by a strong balance sheet. Valuation is a key support (low P/E and high dividend yield). Technicals are mixed, with modestly positive momentum signals but the price still below the 100/200-day averages.
Positive Factors
Conservative leverage / strong balance sheet
The company’s low debt-to-equity ratio provides durable financial flexibility to fund operations, absorb cyclical shocks, and support working capital or capex without resorting to dilutive financing. That conservatism sustains credit optionality and long-term stability for 2–6 months and beyond.
Negative Factors
Sharp 2025 revenue decline
A 40.5% revenue drop in 2025 indicates significant structural or demand setbacks that can erode pricing power, utilization of fixed-cost capacity and long-term customer relationships. Recovering lost revenue bases can take multiple quarters and strain margins and investment plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative leverage / strong balance sheet
The company’s low debt-to-equity ratio provides durable financial flexibility to fund operations, absorb cyclical shocks, and support working capital or capex without resorting to dilutive financing. That conservatism sustains credit optionality and long-term stability for 2–6 months and beyond.
Read all positive factors
Shandong Weigao Group Medical Polymer Co (1066) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$14.63B
Dividend Yield5.57%
Average Volume (3M)13.05M
Price to Earnings (P/E)9.0
Beta (1Y)1.09
Revenue Growth7.47%
EPS Growth-26.89%
CountryHK
Employees13,310
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.30
Shares Outstanding4,522,332,500
10 Day Avg. Volume11,063,009
30 Day Avg. Volume13,052,760
Financial Highlights & Ratios
PEG Ratio-0.54
Price to Book (P/B)0.85
Price to Sales (P/S)1.53
P/FCF Ratio11.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$4.54Price Target Upside30.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)0.33
Revenue Forecast (FY)HK$13.85B
Shandong Weigao Group Medical Polymer Co Business Overview & Revenue Model
Company Description
Shandong Weigao Group Medical Polymer Company Limited, founded in 2000 and situated in Weihai, People's Republic of China, specializes in the research, development, production, and distribution of disposable medical devices across mainland China. ...
How the Company Makes Money
null...
Shandong Weigao Group Medical Polymer Co Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
74
Positive
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.50B | 13.39B | 13.09B | 13.23B | 13.62B | 13.15B |
| Gross Profit | 6.15B | 6.33B | 6.58B | 6.64B | 7.31B | 7.35B |
| EBITDA | 2.73B | 2.75B | 3.14B | 3.55B | 4.38B | 3.75B |
| Net Income | 1.37B | 1.61B | 2.07B | 2.00B | 2.76B | 2.28B |
Balance Sheet | ||||||
| Total Assets | 35.56B | 36.06B | 34.76B | 33.67B | 33.20B | 30.37B |
| Cash, Cash Equivalents and Short-Term Investments | 8.92B | 9.87B | 8.32B | 7.33B | 7.49B | 7.13B |
| Total Debt | 4.96B | 5.99B | 4.19B | 4.17B | 4.49B | 4.14B |
| Total Liabilities | 9.39B | 10.23B | 9.42B | 9.68B | 9.75B | 9.46B |
| Stockholders Equity | 24.39B | 24.12B | 23.75B | 22.45B | 21.67B | 19.27B |
Cash Flow | ||||||
| Free Cash Flow | 1.08B | 1.72B | 2.19B | 2.11B | 1.10B | 1.92B |
| Operating Cash Flow | 2.80B | 2.55B | 2.79B | 2.80B | 2.21B | 3.04B |
| Investing Cash Flow | 272.14M | -382.91M | -1.10B | -1.39B | -2.57B | -1.48B |
| Financing Cash Flow | -2.57B | -772.65M | -1.60B | -2.16B | -1.02B | -547.92M |
Shandong Weigao Group Medical Polymer Co Technical Analysis
Negative
3.48
Price Trends
3.35
Negative
3.36
Negative
4.13
Negative
Market Momentum
-0.05
Positive
35.14
Neutral
35.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1066, the sentiment is Negative. The current price of 3.48 is above the 20-day moving average (MA) of 3.34, above the 50-day MA of 3.35, and below the 200-day MA of 4.13, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 35.14 is Neutral, neither overbought nor oversold. The STOCH value of 35.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1066.
Shandong Weigao Group Medical Polymer Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
89 Outperform | HK$7.15B | 10.25 | 20.11% | 3.87% | 12.50% | 44.44% | |
78 Outperform | HK$3.16B | 8.92 | 10.50% | 7.20% | 16.25% | 7.80% | |
69 Neutral | HK$16.51B | 66.44 | 5.84% | 0.50% | ― | ― | |
67 Neutral | HK$14.63B | 8.96 | 5.64% | 5.57% | 7.47% | -26.89% | |
67 Neutral | HK$1.40B | 29.18 | 1.10% | 6.56% | -1.64% | -68.67% | |
61 Neutral | HK$7.09B | 24.08 | 9.64% | 0.78% | 34.94% | 12.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:1066
Shandong Weigao Group Medical Polymer Co
3.14
-2.52
-44.47%
HK:1358
PW Medtech Group Ltd.
0.98
-0.48
-33.13%
HK:3600
Modern Dental Group Limited
7.48
2.06
37.88%
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
33.20
1.83
5.83%
HK:6699
Angelalign Technology Inc.
91.60
31.15
51.53%
HK:6929
OrbusNeich Medical Group Holdings Limited
3.75
-0.42
-10.01%
Shandong Weigao Group Medical Polymer Co Corporate Events
Weigao Medical Polymer Sets August Board Meeting to Review Interim Results and Dividend
Jul 27, 2026
Shandong Weigao Group Medical Polymer Company Limited is a Hong Kong-listed Chinese medical device maker specialising in polymer-based healthcare products. The firm supplies hospitals and clinical institutions with disposable and other medical con...
Weigao Holding Boosts Stake in Shandong Weigao Medical Polymer
Jul 14, 2026
Weigao Holding has increased its stake in Shandong Weigao Group Medical Polymer Company Limited, a Hong Kong-listed Chinese medical device maker, through open-market purchases funded with its own capital. The Group specializes in medical polymer p...
Weigao Holding Lifts Stake in Shandong Weigao Group Medical Polymer
Jun 5, 2026
Shandong Weigao Group Medical Polymer Company Limited reported that its controlling shareholder, Weigao Holding, has further increased its stake through open-market purchases of H shares in mid-May 2026. The transactions, funded with Weigao Holdin...
Shandong Weigao Sets Final 2025 Dividend and Clarifies Tax Terms for H Shareholders
May 29, 2026
Shandong Weigao Group Medical Polymer Company Limited has declared a final ordinary dividend of RMB 0.06 per share for the financial year ended 31 December 2025, with shareholder approval obtained on 29 May 2026. The dividend for H shares will be ...
Weigao Medical Polymer Shareholders Approve All AGM Resolutions and Final Dividend
May 29, 2026
Shandong Weigao Group Medical Polymer Company Limited reported that all resolutions proposed at its 29 May 2026 annual general meeting were approved by poll, including the adoption of the 2025 audited financial statements and board and supervisory...
Weigao Controlling Shareholder Lifts Stake, Signaling Confidence in China’s Medical Device Growth
May 14, 2026
Shandong Weigao Group Medical Polymer Company Limited announced that its controlling shareholder, Weigao Holding Company Limited, has increased its stake in the company by purchasing 3,552,800 H shares on the open market on 13 and 14 May 2026. Fol...
Shandong Weigao Posts Q1 Revenue Growth on Strong Device and Packaging Sales
May 8, 2026
Shandong Weigao Group Medical Polymer reported unaudited revenue of about RMB3.35 billion for the first quarter of 2026, representing year-on-year growth of roughly 5.3%. The company said medical devices and pharma packaging delivered high single-...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.